Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase III clinical trial

Dataset ID Technology Samples
EGAD00001006585 Illumina NovaSeq 6000 30

Dataset Description

In our study, we hypothetyzed that CD34progenitors from cases with undetectable Minimal residual Disease (MRD) by flow cytometry would contain cells with leukemic-initiating-potential that could be identified on genetic (rather than phenotypic) grounds by Whole Exome Sequencing.

Who controls access to this dataset

For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. Access to actual data files is not managed by the EGA. If you need to request access to this data set, please contact:

MRD in AML: data from whole exome sequencing
Contact person: Catia Patricia Simoes Pinto
Email: csimoes [dot] 1 [at] alumni [dot] unav [dot] es
More details: EGAC00001001806


You don't have access to the download section.